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ABSTRACT 
The bacterium Pseudomonas aeruginosa may grow in a biofilm structure, which can 
be up to 1000 times more resistant to antibiotics compared to planktonic isolates. The P. 
aeruginosa biofilms have serious implications with regard to infection, especially in 
individuals with weakened immune defenses such as burn and cystic fibrosis patients. 
Antibiotic studies are usually based on planktonic antibiotic susceptibility results, so the 
treatment may be less effective when used in patients. The aim of this study was to further 
screen previously studied cave bacterial isolates with potential activity and determine their 
antimicrobial capabilities against P. aeruginosa biofilms. Three strains; A1A3, RA003 and 
58B were cultured in different media over 10 days, with collections of supernatant on days 2, 
4, 6, 8, and 10.  The MBEC P&G Assay device was used to culture P. aeruginosa biofilms, 
which were then exposed to the collected supernatants. After exposure, the surviving 
biofilms were recovered, and spot plated in order to measure any inhibition of P. aeruginosa. 
Dilution and spot plating were also used to enumerate surviving cells, and give a percent 
survival quantification of antimicrobial activity. As well, Kirby-Bauer disc diffusion assays 
were used to determine the cave isolates’ inhibitory effect on planktonic cells. Scanning 
electron microscopy was used to examine biofilms structures and 16S rRNA sequencing was 
used to identify cave bacterial isolates. The biofilms showed a noticeably decreased percent 
survival when exposed to the cave isolate supernatant. The cave isolate 58B showed to be 
very promising, demonstrating significant reduction in the surviving biofilm cells. This study 
shows that cave bacteria produce antimicrobials that are effective against pathogenic bacteria 
even in a biofilm structure.      
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INTRODUCTION 
Antibiotic Resistance 
 The decline in the discovery of novel antibiotics and rising of antibiotic resistance in 
pathogens has made the discovery of new ones important.  Antibiotics are essential to the 
medical field, and help us combat bacterial and fungal infections, which, according to the 
World Health Organization, cause 16.2% of the world’s deaths per year. The antibiotics work 
by interacting with a bacterium or fungi, and disrupting a certain pathway resulting in the 
organism’s destruction. When the antibiotics are first introduced, there may be a small 
proportion of resistant bacteria in patients, but these bacteria are not yet problematic. Then 
the number of resistant bactereria  may rise to a level where the antibiotic has reduced 
efficiency in the human population, resulting in antibiotic resistant bacteria (Coates and Hu, 
2007). Antibiotic resistance precedes clinical use, and can be found in nature (Hall and 
Barlow, 2004), but has increased due to the over-use in bacterial infection therapies 
(Fernández et al., 2011). From the overuse of antibiotics, some bacteria have seemingly 
undergone an accelerated evolution, and have increased success of surviving antibiotic 
treatment. This has allowed some bacterial species to become “multi-drug resistant” (MDR). 
Through continuous exposure, some bacteria have become resistant to these compounds and 
employ many different defenses. These defenses may be passed through horizontal gene 
transfer, conjugation, or mutations leading to decreased susceptibility (Baquero, 2001). 
Antibiotic resistance may be from bacteria having enzymes that break down the antibiotic, 
reducing the permeability of the bacterial cell, or from changing the target of the antibiotic. 
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An interesting example of a resistant defense is biofilms that are produced by some bacterial 
species.  
Biofilms  
 Biofilms are communities of bacteria encased in a self-synthesized polymeric matrix 
that may adhere to biotic or abiotic surfaces (Hall-Stoodley et al., 2004). The cells of the 
biofilm are typically encased in a matrix of polysaccharides, extracellular DNA (eDNA), and 
proteins (Flemming and Wingender, 2010; Yang et al., 2012).  Bacteria are usually thought 
of as planktonic, single cell organisms, but they predominantly live in multicellular biofilms 
in the environment. Environmental stress results in dysregulation of multiple regulatory 
systems, and the cells will attach to a surface in order to resist the environmental change. The 
formed mature biofilm may release some cells in a dispersive stage in order to colonize new 
areas (Costerton et al., 1999; Hall-Stoodley et al., 2004).  
Biofilms may have water-filled channels that allow for increased nutrient supply. The 
matrix may also contain extracellular enzymes, and cells may show enhanced toxic 
compound excretion, changed metabolic processes and differentiated phenotypes. That is, the 
biofilm creates a gradient of nutrients and oxygen with inner cells having a decreased 
metabolism and cell division relative to the peripheral cells (Costerton et al., 1999; Flemming 
and Wingender, 2010; Hall-Stoodley et al., 2004). This mode of growth protects the bacteria 
from eradication via desiccation, nutrient deprivation and antibiotic treatment (Gaddy and 
Actis, 2009).  Bacteria associated with biofilms may be up to 1000 times more resistant to 
antibiotics compared to planktonic cells, and enables cells in biofilms to persist despite 
intensive antibiotic therapy (Gaddy and Actis, 2009; Mah and O’Toole, 2001). Antibiotic 
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therapy may even trigger biofilm formation if the antibiotics are at a concentration below the 
minimum inhibitory concentration (known as sub-MIC). Bacteria may be exposed to sub-
MIC at the beginning and end of antibiotic therapy. Also, the colony of cells may be thick 
enough such that only low amounts of the antibiotic actually make it to inner cells, resulting 
in sub-MIC (Mah and O’Toole, 2001; Singh et al., 2010). The bacterium Pseudomonas 
aeruginosa is a clinically important organism because it forms resilient biofilms.  
Pseudomonas aeruginosa Pathogen  
 Pseudomonas aeruginosa is a motile, Gram-negative, opportunistic pathogen that is 
prevalent in the medical hospital environment. The pathogen is common in respiratory 
infections and urinary tract infections, and is especially implicated in patients with weakened 
defenses like burn and cystic fibrosis (CF) patients (Morita et al., 2014). The bacterium P. 
aeruginosa is a metabolically versatile microbe that can survive in many different 
environments. It can grow in aerobic and anaerobic conditions and may produce a multitude 
of different virulence factors (Schurek et al., 2012). The pathogenic bacteria may possess 
flagella and type IV pili that can function in adhesion and motility as well as initiation of an 
inflammatory response (Gellatly and Hancock, 2013). Also, Type 3 secretion systems inject 
toxins directly into host cells and breach epithelial cell layers (Hauser, 2009). The bacterium 
P. aeruginosa may also produce proteases that are able to degrade immunoglobulins and 
fibrin, leading to tissue damage (Kipnis et al., 2006). Some other virulence factors include 
exotoxin A, lipases, pyocyanin, and iron chelators (Gellatly and Hancock, 2013). As well as 
possessing many virulence factors, P. aeruginosa is also resistant to many antibiotics. The 
bacterium has intrinsic resistance to many antimicrobials because of an outer-membrane 
barrier, multidrug efflux pumps and endogenous antimicrobial inactivation (Poole, 2011). 
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Most importantly the bacterium can produce a robust biofilm, which is thought to further its 
antibiotic resistance ability. This resistance by P. aeruginosa has allowed it to persist despite 
tough antibiotic therapies so there is a need for new antibiotics.  
Cave Bacteria 
 Caves are extreme habits that may house new microorganisms, which can potentially 
produce many new bioactive compounds. The caves are usually nutrient deprived so these 
organisms must have adapted in order to survive in such an environment (Cheeptham et al., 
2013). In particular, Gram-positive, filamentous actinomycetes have been proven to be a new 
source of antibiotics (Genilloud et al., 2011). Out of 22,500 biologically active compounds, 
45% are from actinomycetes (Bérdy, 2005), and the species Streptomyces accounts for 70% 
of the total antibiotic production (Lam, 2006). Cave actinomycetes are of particular interest 
because of the unique environment that they live in. It is reasonable to hypothesize that 
microorganisms living in caves are subject to regressive evolution, where some non-essential 
traits are lost over time. The extreme environment would result in bacteria losing some genes 
but developing new ones with different metabolic pathways. These new pathways could also 
result in new secondary metabolites, which could be important in drug discovery (Cheeptham 
et al., 2013). 
Activation of Antimicrobial Compounds with Ultraviolet Light 
 There have been many studies on the activation of natural compounds with either full 
spectrum sunlight or ultraviolet light. These studies include the activation of biocidal 
compounds such as plant extracts, cow urine and even some antibiotics (Cheeptham and 
Towers, 2002; Upadhyay et al., 2010; Yuan et al., 2011). In most cases, organic compounds 
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absorb UV light and results in photolytic degradation, but this can be gradual which may 
result in new conformations of the compound (Kim and Tanaka, 2009). In one such study 
UV was used on antibiotics like ciprofloxacin, which resulted in an increase of activity 
against to Vibrio fisheri (Yuan et al., 2011). Our study also used UV light to potentially 
activate natural compounds to determine if they have any increased antimicrobial properties 
against a biofilm.  
Objective    
 The objective of this research was to test the hypothesis that secondary metabolites 
produced by cave actinomycetes will have antimicrobial and/or antibiofilm properties against 
Pseudomonas aeruginosa in a biofilm. This includes determining the most effective cave 
bacteria isolate against P. aeruginosa, as well as the most proficient growth conditions to 
produce that effective secondary metabolite. Three cave bacteria isolates (A1A3, RA003, and 
58B) previously showing activity were cultured for 10 days in different fermentation media, 
with samples taken on each day throughout the fermentation period. Collected samples were 
used to treat P. aeruginosa biofilms using a 96 well plate assay. The antimicrobial activity 
was measured by using dilution series and viable cell counts. A Kirby-Bauer disc diffusion 
assay was used to determine the effect of the supernatant on planktonic cells. Scanning 
electron microscopy was used to examine the biofilms presence and structure. Antibiotic 
susceptibilities of biofilms and planktonic cells compared the difference in resistances to the 
antibiotics. Lastly 16s rRNA sequencing identified the cave isolates’ genera. 
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MATERIALS AND METHODS 
 
Figure 1: Flow diagram representing the sample collection, and exposure of P. aeruginosa to the cave 
bacterial supernatant samples. 
Culturing of Pseudomonas aeruginosa Biofilms in MBEC Device  
The MBEC P&G assay device was used to culture the P. aeruginosa in a biofilm 
formation according to Standard Test Method for Testing Disinfectant Efficiacy against 
Pseudomonas aeruginosa Biofilm using the MBEC Assay (2014). The pathogenic bacteria P. 
aeruginosa (lab strain with unknown strain number) was first subcultured onto a trypticase 
soy agar (TSA) (Appendix A) plate using the four way streak method for isolated colonies. 
The plate was incubated for 18 hours at 35oC, and then inspected after the incubation to 
ensure a pure culture.  
 Once the TSA plate had pure colonies of P. aeruginosa, the biofilm culturing began. 
3.0 mL of sterile trypticase soy broth (TSB) was put into a sterile 16x100 mm glass test tube. 
A sterile cotton swab was used to collect P. aeruginosa colonies from the TSA plate. The 
swab with the bacteria was then deposited into the glass tube with TSB. The sample was 
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brought to a 1.0 McFarland standard using the deposited bacteria. This was achieved by 
taking a 500 uL sample and using a spectrophotometer at 600 nm (1.0 Mcfarland standard; 
OD=0.257 at 600 nm). Once the sample was at a 1.0 McFarland standard, 1.0 mL was added 
to 29 mL of TSB in a 45 mL plastic sterile centrifuge tube (this resulted in a 30x dilution) 
and served as the inoculum. A sterile MBEC P&G assay 96 well plate (Innovotech, Suite 
101, 2011-94 St. Edmonton, AB, Canada) (Figure 2) was then removed from the packaging. 
All 96 wells were aseptically filled with 150 μL of the inoculum previously prepared. The 
MBEC device was then put in a 35oC incubator with an orbital shaker at 100 rpm for 18 
hours. After 18 hours, the MBEC device was removed from the incubator. 
 
Figure 2: The MBEC P&G device used to culture P. aeruginosa into a biofilm formation. The device is 
composed of a 96 well plate with a matching 96 peg lid, with each peg fitting into a well. 
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Scanning Electron Microscopy Preparation and Set-Up: Viewing Pseudomonas 
aeruginosa 
The pegs with the P. aeruginosa biofilms were then removed from the lid of the 
MBEC device. This was achieved by using sterilized (flamed) needle nose pliers, grasping 
the pegs closed to the lid, and breaking the peg from the lid. The pegs were then put in 0.9% 
saline solution for one minute to remove any planktonic cells. The pegs were then placed 
horizontally on a stub (Specimen mount, pin type, slotted head) with carbon tape, and were 
loaded into the chamber of the Zeiss LS EVO SEM. The operating conditions used were: the 
vacuum at EP 60 Pa, accelerating voltage at 20 kV, filament amperage 1.684 A, spot size 100 
pA, working distance 12 mm and the VPSE G3 detector (personal communication with Dr. 
Cindy Ross Friedman). The resulting images were adjusted for brightness and contrast with 
Microsoft Word tools to achieve the best picture quality. 
 
Culturing of Cave Bacteria Isolates 
 The screening of cave bacteria isolates used three different isolates that previously 
showed activity against P. aeruginosa in a biofilm formation (Mason, 2015). The three 
strains used were RA003, A1A3, and 58B because they showed the ability to inhibit 
biofilms. These samples originally came from a volcanic cave at Wells Gray Provincial Park 
in British Columbia. Some samples came from agar plates stored in a 4oC fridge, and some 
from storage in 10% glycerol in 96 well plates at a temperature of -70oC (cryopreservation). 
Samples on agar plates had colonies removed with a sterile loop, and deposited on fresh 
Hick-Tresner (HT) (Appendix A) agar plates. The deposited sample was streaked for isolated 
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colonies using the 4-way streak method in order to achieve pure colonies of the cave isolates. 
Samples form cryopreservation were allowed to thaw slightly to liquid, then 10 μL samples 
were removed, deposited on HT agar plated and streaked for confluent growth. These 
samples were then used to inoculate new HT agar plates, which were then streaked for 
isolated colonies in order to obtain pure cultures. These plates were incubated at 25oC for 7 
to 10 days and checked for pure colonies. Plates with mixed growth were then cultured again 
to obtain pure samples. Plates with pure growth were parafilmed and stored at 4oC for later 
use. Colony morphology, Gram-staining and microscopy were used to confirm samples were 
isolates from the previous studies. 
 The three isolates were then used to inoculate test tubes containing different broth 
media. The 16X100 mm test tubes were filled with 6 mL of either V-8 juice, International 
Streptomyces Project #2 (ISP2), or R2A fermentation media (Appendix A), then autoclaved 
at 121oC for 15 minutes. Then 0.5x0.5 cm square plugs were aseptically cut out of the agar 
plates containing colonies of the desired cave bacterial isolate. These plugs were then put in 
the appropriate test tubes and cultured at 25oC for 10 days with 100 rpm of agitation in an 
orbital shaker (New Brunswick Scientific Innova 42).  
 The samples of the supernatant from each tube were taken at days 2, 4, 6, 8, and 10. 
The test tubes were removed from the incubator and put on a sterilized bench. Then 800 μL 
samples were removed from each tube with care taken not to gather any cellular debris 
present. The 800 μL samples were then put into 1.0 mL Eppendorf tubes and stored at -20oC 
until used.  
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Antimicrobial Exposure  
The MBEC device was used to perform antimicrobial exposures. The MBEC device 
was removed from the incubator; the peg lid was removed and rinsed once in 0.9% saline 
solution for 1 minute (Figure 3). The supernatant collected from the cave bacteria samples 
was thawed in the 1.0 mL Eppendorf tubes. The tubes were then put in a centrifuge at 5000 
rpm for 2 minutes. Any remaining cell debris would then be forced to the bottom of the 
Eppendorf tube. A sterile Nunc 96 well plate (washed with 2% Virkon, 70% ethanol, then 
exposed for 20 minutes to UV light) was used for the antimicrobial exposure and deemed the 
“challenge plate.” The wells for the UV treated samples were filled with 200 μL of the 
supernatant from the appropriate cave bacteria sample with triplicates of each. The 96 well 
plate with the supernatant was then exposed for 30 minutes to UV light (254 nm) in a 
Labconco Class II biological safety cabinet.  
 
Figure 3: Diagram of rinsing procedure used for preparation for the initial removal, challenge plate and 
recovery plate (Ceri et al., 1999). 
The Non-UV samples and controls were then added to the 96 well plates. The wells 
for the Non-UV treated samples were filled with 200 μL of the supernatant from the 
appropriate cave bacteria sample. The controls were then added to the appropriate wells: 
Sterile TSB, 2% Virkon, sterile V8, sterile R2A, sterile ISP2 and sterile 1.0 N HCl or water 
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(Figure 4). The growth controls would be those biofilms exposed to only sterile TSB, and the 
fermentation media controls would be biofilms exposed to the sterile V8, R2A, ISP2, and 0.1 
N HCl or water. The Positive control was the biofilms that were exposed to a 2% Virkon 
solution (A disinfectant effective against P. aeruginosa), as well as the antibiotics 
Tetracycline HCl (120, 60, 30, and 10 μg/mL) and Ciprofloxacin in 0.1 N HCl (10, 5, 2.5 and 
0.5 μg/mL) or Ciprofloxacin HCl (10, 5, 2.5 and 0.5 μg/mL).  
 
Figure 4: Challenge plate schematic containing the 3 cave bacteria isolate samples with UV and Non-UV 
treatments cultured in R2A, ISP2, and V8 media. There are 2 antibiotics used in four concentrations: 
Tetracycline HCl at 120, 60, 30, and 10 μg/mL and Ciprofloxacin at 10, 5, 2.5, and 0.5 μg/mL. Also there 
is 2% Virkon controls, 0.1 N HCl (or sterile water) controls and sterile media controls (R2A, ISP2, and 
V8). 
 
The peg lid from the MBEC device (after rinse [Figure 3]) was placed in the 
challenge plate with the appropriate orientation. The peg lid with the Challenge plate was 
then incubated at 35oC (no shaking) for 18 hours after which the MBEC device was removed 
from the incubator. 
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Neutralization of the Antimicrobial and Recovery of Surviving Bacteria 
After the peg lid and challenge plate was removed from the incubator, the peg lid was 
rinsed twice in 0.9% saline solution for 1 minute each wash. A sterile Nunc 96 well plate had 
all 96 wells aseptically filled with 200 μL of D/E neutralizing broth (Appendix A). The peg 
lid was then placed in the D/E neutralizing broth for 1 hour to neutralize the antimicrobials. 
The peg lid was then placed in a sterile 96 well plate with all 96 wells filled with 200 μL of 
TSB (deemed “recovery plate”). The peg lid and recovery plate were then sonicated for 30 
minutes to remove the biofilm from the pegs.  
Two large plates (Figure 5), each filled with 250 mL of TSA, were used to check the 
results of the antimicrobial exposure. Each plate was divided into 49 sections, each with the 
appropriate sample area (Non-UV treated, UV treated, controls etc.). Then, 10 μL from each 
well of the recovery plate was spot plated onto the appropriately labelled square. The two 
TSA plates were then incubated at 35oC for 18 hours, and the recovery plate was put in a -
4oC fridge. 
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Figure 5: Example of Large TSA plates used to visually determine growth of P. aeruginosa (Picture after 
18 hours of incubation in 35oC). 
The TSA plates after 18 hours were removed and visually inspected to determine if 
any samples had no growth or reduced growth. Any samples showing no growth or reduced 
growth were spot plated to enumerate the colonies and to determine the CFU/mL. The 
recovery plate with the same sample on the TSA plate was used to make 4 dilutions from 10-1 
to 10-4. The dilutions then had 10 uL removed and spot plated onto TSA plates. As well the 
P. aeruginosa growth controls (only exposed to TSB) and sterile media controls (R2A, ISP2, 
and V8) were also diluted the same and spot plated onto TSA plates. These TSA plates were 
then incubated at 35oC for 18 hours.  
After 18 hours, the TSA plates were removed from the incubator. The TSA plates had the 
cell colonies enumerated in order to determine the CFU/mL. The CFU/mL for each sample 
was then subjected to a 2 sample T test with pooled variances (after testing data for normality 
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and equal variance) to determine if the difference was significant. A P value of <0.05 was 
considered significant. A sample that showed 0 CFU/mL of surviving bacteria was 
designated bactericidal or if the concentration was known, then it was the minimum biofilm 
eradication concentration (MBEC). 
Kirby-Bauer Disc Diffusion Assay to Determine Planktonic Antimicrobial 
Activity  
The standard Kirby-Bauer (KB) disc diffusion assay (Bauer et al., 1966; Wilkins et 
al., 1972) was used to determine the antimicrobial activity of the cave isolates against 
planktonic P. aeruginosa. The discs used were 8 mm Advantec paper discs (Tokyo, Japan) 
that had previously been autoclaved to sterilize them. Each cave bacterial isolate sample was 
put on the discs in replicates of three. The antibiotics tetracycline HCl (120, 60, 30, and 10 
μg/mL) and ciprofloxacin (10, 5, 2.5 and 0.5 μg/mL) or ciprofloxacin HCl (10, 5, 2.5 and 0.5 
μg/mL) as well as 2% Virkon were used as positive controls. Additionally, sterile growth 
media (R2A, ISP2 and V8), sterile TSB, and sterile 0.1 N HCl were also used as negative 
controls. Each of the UV treated cave bacteria isolate samples had 80 μL pipetted onto each 
disc, and the discs were then exposed for 30 minutes to UV light (254 nm) in a Labconco 
Class II biological safety cabinet. Then 80 μL of the non-UV samples and controls were then 
pipetted onto the discs. All the discs including UV, non-UV and control discs were allowed 
to dry for 45 minutes.  
 Large square agar plates were used to carry out the Kirby-Bauer disc diffusion assay. 
Two plates were used to accommodate all cave bacterial isolates and controls. Two 250 mL 
flasks were prepared containing 200 mL each of molten Trypticase soy agar which was 
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autoclaved at 121oC for 15 minutes. A sterile cotton swab was used to collect P. aeruginosa 
colonies from the TSA plate. During this time two 16x100 mm test tubes had 5 mL of sterile 
TSB pipetted into them. Then P. aeruginosa colonies were collected from a previously 
cultured TSA plate and deposited into each of the test tubes. Each test tube was brought to a 
1.0 McFarland standard using the deposited bacteria. This was achieved by taking a 500 uL 
sample and using a spectrophotometer at 600 nm (1.0 Mcfarland standard; OD=0.257 at 600 
nm). After the molten Trypticase soy agar flasks were autoclaved, the flasks were put into a 
55oC water bath so the molten agar to equilibrate to the same temperature. At this point 2 mL 
of the prepared P. aeruginosa inoculum from one test tube was deposited into the 200 μL of 
molten TS agar (1% v/v), and then repeated with the other test tube and flask. Each flask was 
then poured into sterile large square plates and allowed to solidify. The previously prepared 
discs were then deposited onto the inoculated large square agar plates in alternating rows of 8 
and 7 discs (Figure 6). The plates were then incubated at 35oC for 18 hours, removed and 
inhibitory zones were measured in millimeters. A sample showing an inhibitory zone was 
designated as having an inhibitory effect and if the concentration was known, then it was the 
minimum inhibitory concentration (MIC).      
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Figure 6: Example of large square agar plates with discs containing cave bacteria isolate samples, and 
controls used to assess the antimicrobial activity of each sample. The diameters of the dark inhibitory 
zones that encircle each disc were measured to assess the antimicrobial activity.  
Molecular Identification of Pseudomonas aeruginosa and Cave Bacterial Isolates 
by 16S rRNA gene sequencing 
In order to prepare for the gene sequencing, fresh agar plates were used to culture the cave 
bacterial isolates as well as P. aeruginosa. The cave bacteria were inoculated onto new HT 
agar plates, which were then streaked for isolated colonies in order to obtain pure cultures. 
These plates were incubated at 25oC for 7 days and checked for pure colonies. P. aeruginosa 
(lab strain with unknown strain number) was cultured onto a trypticase soy agar plate using 
the four way streak method for isolated colonies. The plate was incubated for 18 hours at 
35oC, and then inspected after the incubation to ensure that it was a pure culture. The plates 
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were then sent to Seoul, Korea for 16S rRNA gene sequencing by Macrogen. Sequencing 
used 518F/800R and 27F/1492R primers and performed with Big Dye terminator cycle 
sequencing products, which were resolved on Applied Biosystem model 3730XL automated 
DNA sequencing system at Macrogen. The resulting 16S rRNA sequences were compared 
with the GenBank database by using BLAST.  
 
 RESULTS AND DISCUSSION 
Scanning Electron Microscopy for Viewing Pseudomonas aeruginosa 
 The structure of the P. aeruginosa biofilm was able to be viewed with the Zeiss Evo 
LS SEM. This helped establish that the P. aeruginosa was indeed in a biofilm formation and 
that characteristics such as increased antibiotic resistance would be observed in susceptibility 
tests. The images produced revealed a gradient of single planktonic cells to what appears to 
be mature biofilms. The initial attached cells were near the top of the peg close to the surface 
of the culture media. The biofilms started at the bottom of the peg and continued to where the 
individual cells initially attached. As seen in Figure 7A, starting in the top left of the image, 
small dots are visible, which would characterize the single planktonic P. aeruginosa. Figure 
7B shows planktonic cells that appear to have the intermediate shape known as coccobacillus 
which would represent P. aeruginosa. Continuing from the top left to bottom right of Figure 
7A, there seems to be aggregation of cells into clusters characteristic of a biofilm, more 
specifically microcolonies.  In this same image, channels are apparent throughout the 
microcolony and mature biofilm portion. These water filled channels enable enhanced access 
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of nutrients throughout the biofilm and allow thicker biofilm areas to have enough resources 
to survive (Costerton et al., 1999; Flemming and Wingender, 2010; Hall-Stoodley et al., 
2004). Also, Figure 7C shows a much more rounded structure which appears to be slightly 
raised from the rest of the biofilm. This mushroom-like structure is usually indicative of a 
mature portion of the biofilm and has been shown to have high amounts of eDNA (Allesen-
Holm et al., 2006).  Overall the SEM under partial vacuum produced images with good 
resolution which could be used to identify components of the biofilm. Similarly, Alhede et 
al., (2012) used environmental conditions with the SEM to obtain similar images to this 
study. They used biofilm samples placed in the SEM chamber with minimal preparation and 
used a partial vacuum. 
 
Figure 7: SEM images of P. aeruginosa Biofilms viewed with Zeiss Evo LS SEM; A) Image of Biofilm 
showing planktonic cells to mature biofilms; B) Image of planktonic cells C) Image of mature biofilm 
with mushroom like colonies( left arrow indicates water channels and right arrow indicates mushroom 
like colonies)   
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  Antimicrobial Activity of Cave Bacterial Isolates Observed with Spot Plating 
 All three strains, A1A3, RA003 and 58B showed inhibitory activity against 
Pseudomonas aeruginosa biofilms. Similar to results  seen in a previous study (Mason, 
2015), these isolates did not show any inhibitory activity until day 8. Previously these strains 
did not produce metabolites that inhibited biofilms until day 7, and lost the activity by day 11 
(Mason, 2015). Furthermore the Kirby-Bauer disc diffusion assay showed similar results 
with none of the cave isolates exhibiting inhibition of P. aeruginosa with sample days 2, 4, 6, 
8, and 10.  The sample days 2, 4, 6, and 10 had no indication of reduced growth after plating 
out surviving biofilms so those days did not have the colony numbers enumerated or 
CFU/mL calculated. Day 8 visually showed reduced or changed colony morphology 
compared to the growth controls (R2A, ISP2, V8 and TSB). The recovery 96 well plated was 
used to make dilutions, spot plate the dilutions, and enumerate the colonies to determine the 
CFU/mL (Figure 8).  
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Figure 8: The number of samples produced by the cave bacteria that showed antimicrobial activity 
against P. aeruginosa in a biofilm or planktonic form.   
  
 The day 8 samples showed all three strains (A1A3, RA003, and 58B) having an 
inhibitory effect against the biofilms. This agrees with the preliminary study where all three 
had inhibitory activity at day 7(Mason, 2015). The colony spots of the cave isolate samples 
were compared to the TSB control (biofilm only exposed to TSB) colony spots (Figure 9 I). 
A1A3 cultured in V8, and not exposed to UV (Non-UV) reduced the colony spot in replicate 
1. However the replicates 2 and 3 did not show reduced or changed colony morphology 
compared to the controls (Figure 9 A). The cave isolate RA003 cultured in R2A Non-UV 
also showed some inhibition in replicate 1 with the colony spot having colonies spread out 
rather than one solid colony spot. However the replicates 2 and 3 did not show visible 
inhibition (Figure 9 B). The cave isolate RA003 cultured in ISP2 Non-UV also had a reduced 
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colony spot, with only a few smaller colonies present. The replicates 2 and 3 had no visible 
reduction in the colony spot and probably were not affected (Figure 9 C).   The cave isolate 
RA003 cultured in V8 Non-UV showed a smaller colony spot overall indicating some 
inhibitory effect. The replicates 2 and 3 did not visibly show any inhibition (Figure 9 D). The 
cave isolate RA003 V8 with UV exposure showed some inhibition with the colony spot of 
replicate 3 showing a lighter colony colour possibly from reduced cells. The replicates 1 and 
2 did not show any inhibition (Figure 9 E). The cave isolate sample 58B R2A Non-UV 
completely eradicated the biofilm in replicate 1 evident by the no colony spot. The replicates 
2 and 3 did not show any visible colony spot reduction (Figure 9 F).  The sample 58B V8 
Non-UV had replicate 1 having a colony spot with small spread out colonies rather than one 
large colony spot indicating biofilm inhibition. The replicates 2 and 3 did not visibly show 
any reduction in the colony spot (Figure 9 G). Lastly the sample 58B V8 UV had replicates 2 
and 3 showing no colony spot indicating complete biofilm eradication. However, replicate 1 
did not show any inhibition (Figure 9 H) (Appendix B).  
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Figure 9: Results of spot plating surviving P. aeruginosa biofilms onto TSA plates after exposure to Day 8 
samples: A) A1A3 V8 Non-UV B) RA003 R2A Non-UV C) RA003 ISP2 Non-UV D) RA003 V8 Non-UV 
E) RA003 V8 UV F) 58B R2A Non-UV G) 58B V8 Non-UV H) 58B V8 UV I) Sterile TSB. The numbers 1, 
2, and 3 denote replicate number of each sample.  
Antimicrobial Activity of Cave Bacterial Isolates Determined with Calculation of 
CFU/mL  
The day 8 samples that visually showed reduction of the biofilm demonstrated by an 
abnormal or absent colony spot on the TSA plates had the CFU/mL calculated. The 
calculated CFU/mL for each set of sample replicates agreed with the visual colony spot on 
the TSA plates. That is, if the colony spot was reduced, than the CFU/mL for that replicate 
reflected a decreased CFU/mL when compared to the TSB control. The calculated CFU/mL 
for each growth control (R2A, ISP2 and V8) was compared to the TSB control using a 2 
sample T-test to confirm that the media had no effect on the P. aeruginosa biofilms. The P-
value for each comparison of media to TSB control was greater than 0.05 meaning that there 
was no significant difference. This means that the R2A, ISP2 and V8 media did not affect the 
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P. aeruginosa biofilms. The cave bacteria isolate samples were also compared in a similar 
fashion with the use of a 2 sample T-test.  The samples exposed to A1A3 V8 Non-UV, 
RA003 R2A, ISP2 and V8 Non-UV, 58B R2A Non-UV and RA003 V8 UV all had P-values 
greater than 0.05 and that the difference in CFU/mL was not significant. The biofilms 
exposed to 58B V8 Non-UV and 58B V8 UV both showed a significant difference (P-value 
less than 0.05) between the CFU/mL for these samples compared to the TSB control (Table 
1). This would suggest that there was some metabolite in the supernatant samples from the 
58B cave isolate cultured in V8 medium and was active with and without UV exposure.  The 
cave isolate 58B cultured in V8 also showed antimicrobial activity against P. aeruginosa 
biofilms (Figure 10). 
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Figure 10: The average survival of P. aeruginosa cells (in CFU/mL) compared to the TSB control after 
exposure to Day 8 samples (n=3). The error bars indicate standard error of the mean.  
  
 The samples exposed to A1A3 V8 Non-UV, RA003 R2A, ISP2 and V8 Non-UV, 
58B R2A Non-UV and RA003 V8 UV did not show significant reduction of CFU/mL 
compared to the TSB control. However, at least one replicate of each sample did show a 
noticeably reduced CFU/mL. A1A3 V8 Non-UV replicate #1 had a CFU/mL of 2.8x104 
which is noticeably different than the TSB average of 7.6x106 CFU/mL. RA003 in R2A, 
ISP2 and V8 Non-UV also had one replicate with an observable difference; 3.5x104, 2.8x104, 
and 4.5x104 CFU/mL respectively. As well 58B R2A Non-UV had one replicate of 4.5x105 
CFU/mL which differs slightly from the TSB control of 7.6x106 CFU/mL (Table 1). This 
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could be due the fact that the three replicates for each sample were actually from separate 
tubes. The tubes were in the same conditions (temperature, humidity, oxygen, etc.) but small 
differences inside the tubes could have resulted in different secondary metabolite production, 
having different antimicrobial efficiency.  
Table 1: Table of each sample from Day 8 that had an antimicrobial effect and P. aeruginosa biofilms.  
The surviving cells (CFU/mL) from the biofilms after exposure were calculated from the spot plating the 
cells. The three replicates were used to find the average CFU/mL and then the average percent survival 
by taking the sample average and dividing it by the TSB control. The two sample T test (n=3) was used to 
find if the surviving cell percentage was the same between biofilms exposed to the cave isolate samples 
and the TSB control.    
Sample Surviving Cells After Exposure 
(CFU/mL) 
Average 
CFU/mL 
Average % 
survival 
P value 
comparing 
sample to TSB 
control 
Significantly 
different 
than TSB 
control 
Replicate 
#1 
Replicate 
#2 
Replicate 
#3 
A1A3 V8 
Non-UV 
2.8x104 2.7x107 1.2x107 1.3x107 171.2 0.560 No 
RA003 
R2A 
Non-UV 
3.5x104 6.9x106 2.2x107 9.6x106 127.0 0.783 No 
RA003 
ISP2 
Non-UV 
2.8x104 3.1x105 6.5x106 2.3x106 30.0 0.132 No 
RA003 
V8 Non-
UV 
4.5x104 3.4x106 5.4x106 2.9x106 38.8 0.102 No 
58B R2A 
Non-UV 
4.5x105 7.5x106 6.1x106 4.7x106 61.6 0.315 No 
58B V8 
Non-UV 
7.8x105 1.2x106 1.8x106 1.3x106 16.6 0.001 Yes 
RA003 
V8 UV 
6.8x106 5.8x106 7.4x106 6.7x106 87.7 0.228 No 
58B V8 
UV 
1.1x106 0 0 3.5x105 4.6 0.001 Yes 
R2A 
sterile 
6.1x106 6.2x106 6.8x106 6.4x106 83.8 0.075 No 
ISP2 
sterile 
7.8x106 6.2x106 5.9x106 6.6x106 87.3 0.269 No 
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The Antibiotic and Disinfectant Susceptibilities of P. aeruginosa in a Biofilm 
The controls used for sample days 2, 4, 6, 8, and 10 included 2% Virkon and 
antibiotics which had different effects in this sample day. The positive control, 2% Virkon, 
had biocidal properties, and resulted in the complete eradication of the biofilm. After the spot 
plating the Virkon exposed samples, there was no visible growth on the TSA plate. This 
would suggest that Virkon completely killed the P. aeruginosa biofilm. The biocidal activity 
of Virkon has previously been studied (Hernndez et al., 2000), and found that it is effective 
after 5 minutes of contact time with bacteria. Hernndez et al., (2000) found that 5 minutes of 
contact to P. aeruginosa had complete biocidal activity, and therefore 0 CFU/mL. 
Furthermore this study showed that P. aeruginosa biofilms exposed to Virkon for 18 hours 
also resulted in 0 CFU/mL. Tetracycline HCl (120, 60, 30, and 10 μg/mL) and ciprofloxacin 
(10, 5, 2.5 and 0.5 μg/mL) were both used but showed different effectiveness.  
The antibiotic tetracycline HCl at a 120, 60, 30, and 10 μg/mL had no inhibitory 
effect against the P. aeruginosa biofilms. The colony spot of the biofilm exposed to 
tetracycline even at a concentration as high as 120 μg/mL did not show any sign of 
inhibition. Tetracycline is a broad spectrum antibiotic with activity against Gram positive and 
Gram negative bacteria. It works by inhibiting protein synthesis by preventing the attachment 
aminoacyl-tRNA to the ribosomal acceptor (A) site (Chopra and Roberts, 2001). However P. 
aeruginosa is intrinsically resistant to tetracycline due the MexAB/MexXY efflux systems. 
V8 
sterile 
6.4x106 7.8x106 7.0x106 7.1x106 93.0 0.420 No 
TSB 7.1x106 7.3x106 8.4x106 7.6x106 N/A N/A N/A 
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The efflux pumps remove the molecule from the cell before it can reach toxic concentrations 
(Morita et al., 2001) therefore tetracycline is generally not used against P. aeruginosa.  
The antibiotic ciprofloxacin (dissolved in 0.1 N HCl) at 10, 5, 2.5 and 0.5 μg/mL was 
used as a positive control on days 2, 4, 6, and 8. This antibiotic showed no colony spots on 
the TSA plates indicating biocidal activity. However, the control with only 0.1 N HCl also 
had no colony spot indicating complete biocidal activity. This would suggest that it was not 
the ciprofloxacin alone that was able to eradicate the P. aeruginosa biofilms. Most likely the 
0.1 N HCl did not having enough nutrients to sustain the cells. The Kirby-Bauer disc 
diffusion assay (discussed later) showed that 0.1 N HCl had no inhibitory effect on P. 
aeruginosa in a planktonic state.  However with the day 10 samples, ciprofloxacin HCl was 
used (dissolved in water) as a positive control at 10, 5, 2.5 and 0.5 μg/mL. When 
ciprofloxacin HCl was used against P. aeruginosa biofilms, it had biocidal effects. Since 
ciprofloxacin is dissolved in water, it was most likely the antibiotic that had biofilm 
eradication effect. At concentrations of 10 and 5 μg/mL it had complete biocidal activity and 
eradicated the biofilm resulting in 0 CFU/mL. The antibiotic is a fluoroquinolone and targets 
DNA gyrase which then inhibits cell division (Poole, 2011). The 5 μg/mL concentration 
represents the MBEC of ciprofloxacin HCl on P. aeruginosa. This MBEC agrees with other 
values found which put the MBEC of P. aeruginosa (ATCC 27853) at 4 μg/mL (Ceri et al., 
1999) but a more recent study put it in the range of 0.25-8 μg/mL (same strain) (Dosler and 
Karaaslan, 2014).    
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Table 2: The surviving cells (CFU/mL) of the P. aeruginosa biofilms after exposure to Ciprofloxacin HCl 
(day 10 exposures). 
Ciprofloxacin 
HCl (μg/mL) 
Replicate #1 Replicate #2 Replicate #3 Average 
CFU/mL 
10 0 0 0 0 
5 0 0 0 0 
2.5 5.6x105 8.0x105 7.2x105 6.9x105 
  0.5 4.7x105 5.6x105 4.3x105 4.9x105 
 Antimicrobial Activity of cave Bacterial Isolates on Planktonic P. aeruginosa 
 The day 2, 4, 6, 8 and 10 samples were also used in a KB disc diffusion assay but none of 
the strains in any sample demonstrated any inhibition of P. aeruginosa on agar plates. Oddly 
even day 8 samples which exhibited antimicrobial effects against the biofilms, did not have 
an effect on planktonic P. aeruginosa. The day 8 samples were used in the KB disc diffusion 
assay 5 days after they were used in the Biofilm assay. When the samples were initially used, 
they were stored at -20oC, but after they were stored at 4oC, so it is possible that the higher 
temperature resulted in chemical changes to the molecules in the samples, rendering them 
ineffective against P. aeruginosa. However, an alternative idea is that the cave isolate 
supernatant inhibited the biofilm rather than killing the cells. Since the supernatant samples 
did not inhibit the planktonic cells, but did reduce the biofilms, it is possible that the cave 
isolate supernatants actually were able to disrupt the biofilms without killing the cells within.    
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The Antibiotic and Disinfectant Susceptibilities of P. aeruginosa in a Planktonic 
Form 
The same positive controls of 2% Virkon, tetracycline HCl, and ciprofloxacin (HCl) 
were used with the same concentrations as the biofilm assays. The 2% Virkon in day 2, 4, 6, 
8, and 10 showed an inhibitory zone (too small to measure) around the discs. The diameter 
may have been small because of the chemical composition of Virkon. Virkon is composed of 
peroxygen compounds including Potassium peroxymonosulfate, which is a negatively 
charged particle, making it difficult to diffuse through the agar, which is also negatively 
charged. This idea is again consistent with that of Hernndez et al., (2000), which found that 
Virkon had bactericidal effects on P. aeruginosa.  
The antibiotic tetracycline HCl also showed inhibitory activity when used in the KB 
disc diffusion assay. For days 2, 4, 6, 8, and 10, tetracycline HCl at 120 μg/mL showed an 
inhibitory zone. Days 2, 4, and 8 showed measureable inhibitory zones that ranged from 10 
to 14 mm. Also Days 4 and 8 showed inhibitory zones at 60 μg/mL, but were too small to 
measure. So the 60 μg/mL could be thought of as the MIC of tetracycline HCl on P. 
aeruginosa. This is within the range of other MIC’s found for P. aeruginosa (various lab 
strains such as PA01) which were 0.5-64 μg/mL (Li et al., 1994; Morita et al., 2001).  
The antibiotic ciprofloxacin (dissolved in 0.1 N HCl) was used for sample days 2, 4, 
6, and 8 and ciprofloxacin HCl was used for sample day 10.  Both showed very similar 
inhibitory activity when used in the KB disc diffusion assay. A control with just 0.1 N HCl 
was used for days 2, 4, 6, and 8 which showed that it had no inhibitory activity (a different 
result than the Biofilm assay mentioned earlier). For sample days 2, 4, 6, 8, and 10 the 
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ciprofloxacin/ciprofloxacin HCl showed inhibitory zone ranges of 26-19 mm and 18-10 mm 
for concentrations of 10 and 5 μg/mL respectively. Ciprofloxacin/ciprofloxacin HCl at 2.5 
μg/mL showed an inhibitory zone of 12-10 mm for Day 2 then inhibitory zones too small to 
measure for Day 4, 6, 8, and 10. The concentration of 0.5 μg/mL had no inhibitory zone, 
indicating too low of a concentration to have an inhibitory effect on P. aeruginosa. This 
would indicate that 2.5 μg/mL is the MIC which is slightly higher than some other studies 
have found. Some studies put the MIC in a range of 0.1-0.5 μg/mL for various strains of P. 
aeruginosa including ATCC 27853 and PA01 (Ceri et al., 1999; Li et al., 1994; Morita et al., 
2001), but a more recent study showed an MIC range of 0.25-2 μg/mL (Dosler and 
Karaaslan, 2014), which is a value much closer to what this study found.  
Antimicrobial Activity as Compared to Previous Studies with Same Isolates 
The results of this study correspond to earlier studies conducted with the cave isolates 
A1A3, RA003 and 58B. In a preliminary study, these cave isolates showed the ability to 
inhibit P. aeruginosa biofilms resulting in a reduced CFU/mL (Mason, 2015). The 
preliminary study found 58B V8 Non-UV as well as RA003 and A1A3 R2A Non-UV had 
inhibitory effects on biofilms. That study (Mason, 2015) and this one both show that biofilm 
inhibitory molecules are produced by the strains starting on day 7 (result of previous study) 
and day 8 (this study) but lose the activity by day 10 as shown in this study. The current 
study found that A1A3, RA003 and 58B could produce compounds that could inhibit P. 
aeruginosa biofilms. The cave isolate RA003 could produce antimicrobial compounds when 
cultured in R2A, ISP2 and V8 as well as being effective after the supernatant was exposed to 
UV light. This would suggest that RA003 is versatile organism that can grow in a variety of 
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culture media. In the preliminary study, RA003 was found to have inhibitory activity only in 
R2A. The cave isolate 58B was able to produce antimicrobial compounds when cultured in 
R2A and V8 as well. Previously in the preliminary study, 58B was only able to have 
inhibitory effects when cultured in V8.    The cave isolate A1A3 was only able to produce 
antimicrobial compounds when cultured in V8. However in the preliminary study, it 
produced antimicrobial compounds in R2A (Mason, 2015).  
These cave isolates also have similar antimicrobial activities compared to previous 
studies conducted with these strains. The cave isolate A1A3 had antimicrobial effects against 
the Gram-negative bacteria Klebsiella pneumoniae, Escherichia coli and Acinetobacter 
baumannii having inhibitory zones of 11-13 mm when cultured in V8 (Sadoway, 2011) 
similar to this study. Also RA003 has shown activity against  Micrococcus luteus and MDR-
MRSA when cultured in R2A, HT and ISP2, producing zones of inhibition 11-15mm 
(Alnahdi, 2014). This shows again that the cave isolate RA003 is able to produce 
antimicrobial compounds in a variety of media. Rule, (2012) found the cave isolate 58B had 
antimicrobial effects against Mycobacterium smegmatis and A. baumannii when cultured in 
HT. Sadoway, (2011) found that cave isolate 58B had antimicrobial effects on E. coli but 
only in HT and ISP2, not when cultured in V8 medium.  Furthermore Alnahdi, 2014 found 
that the cave bacteria isolates cultured in R2A medium had high antimicrobial activities. Her 
study showed the 58B cave isolate cultured in R2A had antimicrobial effects against 
Micrococcus luteus, M. smegmatis, and Candida albicans. In addition, the RA003 cave 
isolate had antimicrobial activity against M. luteus when cultured in R2A medium. Alnahdi, 
(2014) identified R2A broth to be the optimal fermentation broth because the zones of 
inhibition for 58B and RA003 were larger when grown in R2A as compared to HT broth. 
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This study showed R2A was able to support isolates 58B and RA003 to make antimicrobial 
compounds, but it did not seem to be the most effective culture medium. The V8 culture 
medium was able to sustain A1A3, RA003 and 58B, which caused all three strains to 
produce compounds that could inhibit P. aeruginosa biofilms. The most interesting finding 
was that 58B cultured in the V8 medium produced significant reduction of the biofilms with 
and without UV treatment. In fact, the UV treated 58B V8 supernatant yielded a compound 
that in two replicates resulted in complete biofilm eradication, an impressive result 
considering an impure sample.    
Furthermore this study found that only one of the cave isolates showed antimicrobial 
activity after exposure to UV light for 30 minutes; however, it was the most effective sample. 
Sadoway, (2011) found that the cave isolate 58B only had an antimicrobial effect against E. 
coli when not exposed to UV. Also Rule, (2012) found that the same cave isolate again only 
had activity against M. smegmatis and A. baumannii when not exposed to UV light. In this 
study, it is possible that the UV light actually increased the antimicrobial compound’s 
antimicrobial effect by causing a conformation change. One study showed that the antibiotics 
oxytetracycline, doxycycline and ciprofloxacin had increased inhibition against Vibrio fisheri 
when exposed to 3816 mJ/cm2  of UV fluence (energy rate) (Yuan et al., 2011).   
Identities of Cave Bacterial Isolates and P. aeruginosa 
 The clinically useful antibiotics used to treat P. aeruginosa are generally 
carbapenems, fluoroquinolones, and aminoglycosides (Morita et al., 2014).  Since these cave 
bacterial isolates produced antimicrobial compounds that inhibited P. aeruginosa, it is 
possible that the compounds may resemble one of the previous antibiotics mentioned. In fact, 
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carbapenems and aminoglycosides have been known to be produced by Streptomyces species 
(Poole, 2011). The cave isolates A1A3 and 58B were shown to be Gram positive filamentous 
bacteria, which is consistent with Streptomyces species identification. Furthermore the 16S 
rRNA sequencing also showed that both A1A3 and 58B were Streptomyces species with 99% 
shared similarity and 100% query coverage (Table 3). However due to the similarity and 
query coverage, a species could not be discerned for either isolate. The cave isolate RA003 
was a Gram positive rod shaped bacterium and the 16S rRNA sequencing agreed with this. 
The sequencing showed that the cave isolate RA003 was in the Bacillus genus but again due 
the similarity and query coverage a species could not be discerned (Table 3). The gene 
sequencing also showed that the pathogenic bacterium was P. aeruginosa but a strain could 
not be concluded based on the similarity and query coverage (Table 3). Members of the  
Bacillus genus has previously been able to produce bacteriocins (antimicrobial peptides) 
against a wide variety of bacteria. Some examples the bacterium’s inhibitory effects are: 
Listeria monocytogenes ATCC 19111, Pseudomonas fluorescens ATCC 11251, 
Staphylococcus aureus ATCC 25923 and E. coli (Abdel-Mohsein et al., 2011; He et al., 
2006; Kayalvizhi and Gunasekaran, 2008).  
Table 3: Identification of the organisms used according to 16S rRNA gene sequencing 
Organism 
Analyzed 
Possible Identity Percent 
Similarity 
Query 
Coverage 
A1A3 Streptomyces fulvissimus strain DSM 40593  99 100 
Streptomyces microflavus strain PM86A  99 100 
58B Streptomyces fulvissimus strain DSM 40593  99 100 
Streptomyces microflavus strain PM86A  99 100 
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RA003 Bacillus pumilus strain Jo2  99 100 
Bacillus altitudinis strain KUDC1731  99 100 
Pseudomonas 
aeruginosa 
Pseudomonas aeruginosa strain SBTPe-001  99 100 
Pseudomonas aeruginosa strain SV1  99 100 
Pseudomonas aeruginosa strain VSS6  99 100 
 
 Microbial natural products are still a major source of new drugs for antibiotic 
production, but must be discovered first. Microorganisms from a wide variety of 
environments have been shown to be able to combat pathogenic bacteria and in some cases 
the biofilms they form. The biofilms are quite often a major cause of the pathogenicity of the 
bacterium in question. The bacterial strains used in this study were isolated from caves found 
in British Columbia, which further solidifies that natural habitats can produce many useful 
bacteria. Recently, a study used bacteria from soil, cave, and rivers to produce cell free 
extracts. The extracts were then used against Staphylococcus aureus biofilms in a 96 well 
microtitre plate, similar to this study. The study found that 55/126 extracts significantly 
inhibited the biofilms due a variety of chemical compounds found in the extracts. Also 40% 
of the extracts were found to contain DNase, which could break down extracellular DNA, a 
major structural component of  some biofilms (Farmer et al., 2014). In another study, 
researchers collected bacterial samples from Magura Cave in Bulgaria. The samples were 
very diverse with respect to bacterial species, and all produced varying compounds such as 
proteases, xanthan lyase and β-glycosidase. Again the researchers found that 75% of the 
collected samples showed antimicrobial activity against Bacillus subtilis ATCC 6633 and 
Pseudomonas aeruginosa NBIMCC 1390 in a biofilm (Lazarkevich et al., 2013). Some 
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marine bacterial isolates have been studied as well for their biofilm effects. In one study 
bacterial strains from sediment in the Palk Bay region were isolated, then used to produce 
cell free extracts. These extracts did not show biofilm biocidal effects, but could inhibit the 
biofilms from forming. The marine isolates Bacillus indicus MTCC 5559 and Bacillus 
pumilus MTCC 5560 showed mature biofilms of P. aeruginosa being inhibited by 70-74% 
(Nithya et al., 2010).    
CONCLUSIONS AND FUTURE WORK 
Cave bacteria, including actinomycetes, continue to be important in the discovery of 
new bioactive compounds. The cave bacteria isolates A1A3, RA003, and 58B used in this 
project continued to have inhibitory activity against another pathogenic bacteria 
Pseudomonas aeruginosa. Of the 90 total supernatant samples collected from culturing for 2, 
4, 6, 8 and 10 days (3 strains, 3 different media, 2 treatments, and 5 different days) only 8 of 
them showed inhibitory activity (approximately 9%) . These samples were all from the Day 8 
collection, but only 2 of the samples showed significant inhibition of the P. aeruginosa 
biofilms. Since the samples had no effect on the planktonic cells, it is reasonable to think that 
there was a biofilm dispersal effect rather than a bactericidal effect. The fermentation broths 
of R2A and V8 seemed to be the most effective choices to produce secondary metabolites 
from cave bacteria. The V8 medium did yield antimicrobial secondary metabolites from all 
three strains used. The exposure of UV light did appear to have an activating effect on the 
samples RA003 and 58B both cultured in V8 and 58B turned out to be the more effective, 
having complete biofilm eradication properties. It is promising that these cave bacterial 
isolates produced secondary metabolites that would inhibit biofilms at all. Cells living in a 
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biofilm are more resistant to antimicrobial compounds, so it is impressive that the cave 
isolates could have inhibitory effects without any purification or concentrating. The next step 
would be to take samples from Day 7 to Day 9 in order to pinpoint where the most effective 
secondary metabolite it produced. The culture conditions such as temperature, pH, oxygen 
etc. could also be studied to optimize the antimicrobials produced. As well it would be 
important to purify and identify what specific molecules are present in the cave isolate 
samples in order to decipher the mechanism of action. 
It is obvious now that antibiotic susceptibilities of free-living bacteria are greatly 
reduced as compared to biofilm susceptibilities. The MIC of P. aeruginosa to the antibiotic 
ciprofloxacin HCl is lower (half according to this study) than what is need for the MBEC. 
Using the MBEC 96 well microtitre plate to study susceptibilities of biofilms to 
antimicrobials is essential. This high throughput method allows for more realistic conditions, 
giving more accurate susceptibilities of the organisms in their natural state. Plate counts were 
used in this study to evaluate the biofilm eradication activity of the cave isolates. This 
method is useful because it can distinguish between live and dead cells to give accurate cell 
concentration measurements. However, it is incredibly time intensive, and sometimes prone 
to contamination, which meant doing the trial over again. Using a plate reader would be 
much faster and more efficient than using plate counts. It would be best to use the plate 
reader for the initial biocidal activity, and then confirm the result with the plate counts. This 
would make the process more efficient while still retaining accurate results of whether the 
cells are alive or dead. As well this study used a laboratory strain of P. aeruginosa to 
evaluate the antimicrobial activity of the cave isolate samples. The next step may be to use 
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multi-drug resistant strains of P. aeruginosa from hospitals and determine if the cave 
bacterial isolates are still effective against those strains.   
Overall, the three cave bacteria isolates: A1A3, RA003, and 58B were able to have an 
inhibitory effect against P. aeruginosa biofilms. The Kirby-Bauer disc diffusion assay 
determined that the cave bacterial isolates did not have an effect on planktonic cells. The 
result of these two experiments would suggest that the cave isolates contain biofilm 
disrupting compounds.  The scanning electron microscopy found that the bacteria did grow in 
a biofilm formation on the pegs of the MBEC device. The biofilms proved to be more 
resistant to antibiotics as compared to the planktonic cells. Lastly, the 16s rRNA sequencing 
identified the cave isolates A1A3, RA003 and 58B as the genera Streptomyces, Streptomyces 
and Bacillus respectively.    
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APPENDIX A-MEDIA 
Hickey-Tresner Media 
Yeast Extract 1.0 g 
Beef Extract 1.0 g 
N-Z Amine A 2.0 g 
Dextrin 10.0 g 
dH2O to 1 L 
pH 7.3 
*Media heated to dissolve Dextrin 
 
 
 
 
 
 
 
 
V8 Juice Media 
V8 supernatant 200.0 mL 
CaCO3 3.0 g 
dH2O 800.0 mL 
pH 6.0 
*PC Blue Ribbon Low Sodium V8 juice 
centrifuged at 10,000 rpm for 10 
minutes to collect supernatant  
International Streptomyces Project # 2 
(Yeast-Malt Extract) 
Yeast Extract 4.0 g 
Glucose 4.0 g  
Malt Extract 10.0 g  
dH2O to 1 L 
pH 7.3 
R2A Media 
R2A pre-made 
broth media 
3.15 g 
dH2O to 1 L 
pH 7.0 
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D/E Neutralizing Broth Media 
Pre-made D/E 
Neutralizing 
broth media 
34.0 g 
dH2O to 1 L 
pH 7.6 
Trypticase Soy Broth Media 
BBL pre-made 
Trypticase soy 
broth media 
30.0 g 
dH2O to 1 L 
pH 7.3 
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APPENDIX B-RAW DATA 
Day 2 Biofilm recovery growth check (+=Growth, -= No growth, RED= reduced growth) 
Non A1A3 
R2A 
NON 
A1A3 
ISP2 
NON 
A1A3 V8 
NON 
R003 
R2A 
NON 
R003 
ISP2 
NON 
R003 V8 
NON 
58B R2A 
NON 
58B ISP2 
NON 
58B 
V8NON 
#1 
 
+ + + + + + + + + 
#2 + + + + + + + + + 
#3 + + + + + + + + + 
UV 
 
A1A3 
R2A  
A1A3 
ISP2  
A1A3 V8  R003 
R2A  
R003 
ISP2  
R003 V8  58B R2A  58B ISP2  58B V8 
#1 + + + + + + + + + 
#2 + + + + + + + + + 
#3 + + + + + + + + + 
Antibioti
c 
Tetra 
HCl 
120 
ug/mL 
60 30 10  Cipro 10 
ug/mL 
5 2.5 0.5 
#1 + + + +  - - - - 
#2 + + + +  - - - - 
#3 + + + +  - - - - 
 R2A 
sterile 
ISP2 
sterile 
control 
V8 
sterile 
control 
Sterile 
TSB 
2% 
Virkon 
0.1 N HCl    
1# - - - + - -    
#2 - - - + - -    
#3 - - - + - -    
 
 
Day 4 Biofilm recovery growth check (+=Growth, -= No growth, RED= reduced growth) 
Non A1A3 A1A3 A1A3 V8 R003 R003 R003 V8 58B R2A 58B ISP2 58B 
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R2A 
NON 
ISP2 
NON 
NON R2A 
NON 
ISP2 
NON 
NON NON NON V8NON 
#1 
 
+ + + + + + + + + 
#2 + + + + + + + + + 
#3 + + + + + + + + + 
UV 
 
A1A3 
R2A  
A1A3 
ISP2  
A1A3 V8  R003 
R2A  
R003 
ISP2  
R003 V8  58B R2A  58B ISP2  58B V8 
#1 + + + + + + + + + 
#2 + + + + + + + + + 
#3 + + + + + + + + + 
Antibioti
c 
Tetra 
HCl 
120 
ug/mL 
60 30 10  Cipro 10 
ug/mL 
5 2.5 0.5 
#1 + + + +  - - - - 
#2 + + + +  - - - - 
#3 + + + +  - - - - 
 R2A 
sterile 
ISP2 
sterile 
control 
V8 
sterile 
control 
Sterile 
TSB 
2% 
Virkon 
0.1 N HCl    
1# - - - + - -    
#2 - - - + - -    
#3 - - - + - -    
 
 
Day 6 Biofilm recovery growth check (+=Growth, -= No growth, RED= reduced growth) 
Non A1A3 
R2A 
NON 
A1A3 
ISP2 
NON 
A1A3 V8 
NON 
R003 
R2A 
NON 
R003 
ISP2 
NON 
R003 V8 
NON 
58B R2A 
NON 
58B ISP2 
NON 
58B 
V8NON 
#1 
 
+ + + + + + + + + 
#2 + + + + + + + + + 
#3 + + + + + + + + + 
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UV 
 
A1A3 
R2A  
A1A3 
ISP2  
A1A3 V8  R003 
R2A  
R003 
ISP2  
R003 V8  58B R2A  58B ISP2  58B V8 
#1 + + + + + + + + + 
#2 + + + + + + + + + 
#3 + + + + + + + + + 
Antibioti
c 
Tetra 
HCl 
120 
ug/mL 
60 30 10  Cipro 10 
ug/mL 
5 2.5 0.5 
#1 + + + +  - - - - 
#2 + + + +  - - - - 
#3 + + + +  - - - - 
 R2A 
sterile 
ISP2 
sterile 
control 
V8 
sterile 
control 
Sterile 
TSB 
2% 
Virkon 
0.1 N HCl    
1# - - - + - -    
#2 - - - + - -    
#3 - - - + - -    
 
 
Day 8 Biofilm recovery growth check (+=Growth, -= No growth, RED= reduced growth) 
Non A1A3 
R2A 
NON 
A1A3 
ISP2 
NON 
A1A3 V8 
NON 
R003 
R2A 
NON 
R003 
ISP2 
NON 
R003 V8 
NON 
58B R2A 
NON 
58B ISP2 
NON 
58B 
V8NON 
#1 
 
+ + RED RED RED RED - + RED 
#2 + + + + + + + + + 
#3 + + + + + RED + + + 
UV 
 
A1A3 
R2A  
A1A3 
ISP2  
A1A3 V8  R003 
R2A  
R003 
ISP2  
R003 V8  58B R2A  58B ISP2  58B V8 
#1 + + + + + + + + + 
#2 + + + + + + + + - 
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#3 + + + + + RED + + - 
Antibioti
c 
Tetra 
HCl 
120 
ug/mL 
60 30 10  Cipro 10 
ug/mL 
5 2.5 0.5 
#1 + + + +  - - - - 
#2 + + + +  - - - - 
#3 + + + +  - - - - 
 R2A 
sterile 
ISP2 
sterile 
control 
V8 
sterile 
control 
Sterile 
TSB 
2% 
Virkon 
0.1 N HCl    
1# - - - + - -    
#2 - - - + - -    
#3 - - - + - -    
 
 
Day 10 Biofilm recovery growth check (+=Growth, -= No growth, RED= reduced growth) 
Non A1A3 
R2A 
NON 
A1A3 
ISP2 
NON 
A1A3 V8 
NON 
R003 
R2A 
NON 
R003 
ISP2 
NON 
R003 V8 
NON 
58B R2A 
NON 
58B ISP2 
NON 
58B 
V8NON 
#1 
 
+ + + + + + + + + 
#2 + + + + + + + + + 
#3 + + + + + + + + + 
UV 
 
A1A3 
R2A  
A1A3 
ISP2  
A1A3 V8  R003 
R2A  
R003 
ISP2  
R003 V8  58B R2A  58B ISP2  58B V8 
#1 + + + + + + + + + 
#2 + + + + + + + + + 
#3 + + + + + + + + + 
Antibioti
c 
Tetra 
HCl 
120 
ug/mL 
60 30 10  Cipro 10 
ug/mL 
5 2.5 0.5 
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#1 + + + +  - - + + 
#2 + + + +  - - + + 
#3 + + + +  - - + + 
 R2A 
sterile 
ISP2 
sterile 
control 
V8 
sterile 
control 
Sterile 
TSB 
2% 
Virkon 
sterile 
water 
   
1# - - - + - +    
#2 - - - + - +    
#3 - - - + - +    
 
 
Day 2 KB disc diffusion( +=Inhibition, -= NO inhibition, #= diameter of inhibitory zone in 
mm)  
Non A1A3 
R2A 
NON 
A1A3 
ISP2 
NON 
A1A3 V8 
NON 
R003 
R2A 
NON 
R003 
ISP2 
NON 
R003 V8 
NON 
58B R2A 
NON 
58B ISP2 
NON 
58B 
V8NON 
#1 
 
- - - - - - - - - 
#2 - - - - - - - - - 
#3 - - - - - - - - - 
UV 
 
A1A3 
R2A  
A1A3 
ISP2  
A1A3 V8  R003 
R2A  
R003 
ISP2  
R003 V8  58B R2A  58B ISP2  58B V8 
#1 - - - - - - - - - 
#2 - - - - - - - - - 
#3 - - - - - - - - - 
Antibioti
c 
Tetra 
HCl 
120 
ug/mL 
60 30 10  Cipro 10 
ug/mL 
5 2.5 0.5 
#1 10 - - -  26 18 12 - 
#2 + - - -  25 16 10 - 
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#3 + - - -  24 18 10 - 
 R2A 
sterile 
ISP2 
sterile 
control 
V8 
sterile 
control 
Sterile 
TSB 
2% 
Virkon 
0.1 N HCl    
1# - - - - + -    
#2 - - - - + -    
#3 - - - - + -    
 
 
Day 4 KB disc diffusion( +=Inhibition, -= NO inhibition, #= diameter of inhibitory zone in 
mm) 
Non A1A3 
R2A 
NON 
A1A3 
ISP2 
NON 
A1A3 V8 
NON 
R003 
R2A 
NON 
R003 
ISP2 
NON 
R003 V8 
NON 
58B R2A 
NON 
58B ISP2 
NON 
58B 
V8NON 
#1 
 
- - - - - - - - - 
#2 - - - - - - - - - 
#3 - - - - - - - - - 
UV 
 
A1A3 
R2A  
A1A3 
ISP2  
A1A3 V8  R003 
R2A  
R003 
ISP2  
R003 V8  58B R2A  58B ISP2  58B V8 
#1 - - - - - - - - - 
#2 - - - - - - - - - 
#3 - - - - - - - - - 
Antibioti
c 
Tetra 
HCl 
120 
ug/mL 
60 30 10  Cipro 10 
ug/mL 
5 2.5 0.5 
#1 14 - - -  23 15 + - 
#2 14 - - -  21 17 + - 
#3 13 - - -  20 15 + - 
 R2A 
sterile 
ISP2 
sterile 
V8 
sterile 
Sterile 
TSB 
2% 
Virkon 
0.1 N HCl    
50 
 
control control 
1# - - - - + -    
#2 - - - - + -    
#3 - - - - + -    
 
 
Day 6 KB disc diffusion( +=Inhibition, -= NO inhibition, #= diameter of inhibitory zone in 
mm) 
Non A1A3 
R2A 
NON 
A1A3 
ISP2 
NON 
A1A3 V8 
NON 
R003 
R2A 
NON 
R003 
ISP2 
NON 
R003 V8 
NON 
58B R2A 
NON 
58B ISP2 
NON 
58B 
V8NON 
#1 
 
- - - - - - - - - 
#2 - - - - - - - - - 
#3 - - - - - - - - - 
UV 
 
A1A3 
R2A  
A1A3 
ISP2  
A1A3 V8  R003 
R2A  
R003 
ISP2  
R003 V8  58B R2A  58B ISP2  58B V8 
#1 - - - - - - - - - 
#2 - - - - - - - - - 
#3 - - - - - - - - - 
Antibioti
c 
Tetra 
HCl 
120 
ug/mL 
60 30 10  Cipro 10 
ug/mL 
5 2.5 0.5 
#1 + - - -  23 16 + - 
#2 + - - -  20 15 + - 
#3 + - - -  21 12 + - 
 R2A 
sterile 
ISP2 
sterile 
control 
V8 
sterile 
control 
Sterile 
TSB 
2% 
Virkon 
0.1 N HCl    
51 
 
1# - - - - + -    
#2 - - - - + -    
#3 - - - - + -    
 
 
Day 8 KB disc diffusion ( +=Inhibition, -= NO inhibition, #= diameter of inhibitory zone in 
mm) 
Non A1A3 
R2A 
NON 
A1A3 
ISP2 
NON 
A1A3 V8 
NON 
R003 
R2A 
NON 
R003 
ISP2 
NON 
R003 V8 
NON 
58B R2A 
NON 
58B ISP2 
NON 
58B 
V8NON 
#1 
 
- - - - - - - - - 
#2 - - - - - - - - - 
#3 - - - - - - - - - 
UV 
 
A1A3 
R2A  
A1A3 
ISP2  
A1A3 V8  R003 
R2A  
R003 
ISP2  
R003 V8  58B R2A  58B ISP2  58B V8 
#1 - - - - - - - - - 
#2 - - - - - - - - - 
#3 - - - - - - - - - 
Antibioti
c 
Tetra 
HCl 
120 
ug/mL 
60 30 10  Cipro 10 
ug/mL 
5 2.5 0.5 
#1 10 + - -  20 14 + - 
#2 12 + - -  20 11 + - 
#3 11 + - -  21 12 + - 
 R2A 
sterile 
ISP2 
sterile 
control 
V8 
sterile 
control 
Sterile 
TSB 
2% 
Virkon 
0.1 N HCl    
1# - - - - + -    
52 
 
#2 - - - - + -    
#3 - - - - + -    
 
 
Day 10 KB disc diffusion (+=Inhibition, -= NO inhibition, #= diameter of inhibitory zone in 
mm) 
Non A1A3 
R2A 
NON 
A1A3 
ISP2 
NON 
A1A3 
V8 
NON 
R003 
R2A 
NON 
R003 
ISP2 
NON 
R003 
V8 
NON 
58B 
R2A 
NON 
58B 
ISP2 
NON 
58B 
V8NON 
#1 
 
- - - - - - - - - 
#2 - - - - - - - - - 
#3 - - - - - - - - - 
UV 
 
A1A3 
R2A  
A1A3 
ISP2  
A1A3 
V8  
R003 
R2A  
R003 
ISP2  
R003 
V8  
58B 
R2A  
58B 
ISP2  
58B V8 
#1 - - - - - - - - - 
#2 - - - - - - - - - 
#3 - - - - - - - - - 
Antibio
tic 
Tetra 
HCl 
120 
ug/mL 
60 30 10  Cipro 
10 
ug/mL 
5 2.5 0.5 
#1 + + - -  19 11 + - 
#2 + - - -  19 10 + - 
#3 + - - -  20 11 + - 
 R2A 
sterile 
ISP2 
sterile 
control 
V8 
sterile 
control 
Sterile 
TSB 
2% 
Virkon 
Water 
sterile 
control 
   
1# - - - - + -    
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#2 - - - - + -    
#3 - - - - + -    
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APPENDIX C-CONTIGUOUS SEQUENCES OF BACTERIA  
> Contig - A1A3_518-800  
GGACGAACGCTGGCGGCGTGCTTAACACATGCAAGTCGAACGATGAAGCCTTTCGGGGTGGATTAGTGGC 
GAACGGGTGAGTAACACGTGGGCAATCTGCCCTTCACTCTGGGACAAGCCCTGGAAACGGGGTCTAATAC 
CGGATAACACTCTGTCCTGCATGGGACGGGGTTAAAAGCTCCGGCGGTGAAGGATGAGCCCGCGGCCTAT 
CAGCTTGTTGGTGGGGTAATGGCCTACCAAGGCGACGACGGGTAGCCGGCCTGAGAGGGCGACCGGCCAC 
ACTGGGACTGAGACACGGCCCAGACTCCTACGGGAGGCAGCAGTGGGGAATATTGCACAATGGGCGAAAG 
CCTGATGCAGCGACGCCGCGTGAGGGATGACGGCCTTCGGGTTGTAAACCTCTTTCAGCAGGGAAGAAGC 
GAAAGTGACGGTACCTGCAGAAGAAGCGCCGGCTAACTACGTGCCAGCAGCCGCGGTAATACGTAGGGCG 
CAAGCGTTGTCCGGAATTATTGGGCGTAAAGAGCTCGTAGGCGGCTTGTCACGTCGGATGTGAAAGCCCG 
GGGCTTAACCCCGGGTCTGCATTCGATACGGGCTAGCTAGAGTGTGGTAGGGGAGATCGGAATTCCTGGT 
GTAGCGGTGAAATGCGCAGATATCAGGAGGAACACCGGTGGCGAAGGCGGATCTCTGGGCCATTACTGAC 
GCTGAGGAGCGAAAGCGTGGGGAGCGAACAGGATTAGATACCCTGGTAGTCCACGCCGTAAACGTTGGGA 
ACTAGGTGTTGGCGACATTCCACGTCGTCGGTGCCGCAGCTAACGCATTAAGTTCCCCGCCTGGGGAGTA 
CGGCCGCAAGGCTAAAACTCAAAGGAATTGACGGGGGCCCGCACAAGCAGCGGAGCATGTGGCTTAATTC 
GACGCAACGCGAAGAACCTTACCAAGGCTTGACATATACCGGAAAGCATCAGAGATGGTGCCCCCCTTGT 
GGTCGGTATACAGGTGGTGCATGGCTGTCGTCAGCTCGTGTCGTGAGATGTTGGGTTAAGTCCCGCAACG 
AGCGCAACCCTTGTTCTGTGTTGCCAGCATGCCCTTCGGGGTGATGGGGACTCACAGGAGACTGCCGGGG 
TCAACTCGGAGGAAGGTGGGGACGACGTCAAGTCATCATGCCCCTTATGTCTTGGGCTGCACACGTGCTA 
CAATGGCCGGTACAATGAGCTGCGATGCCGCGAGGCGGAGCGAATCTCAAAAAGCCGGTCTCAGTTCGGA 
TTGGGGTCTGCAACTCGACCCCATGAAGTCGGAGTTGCTAGTAATCGCAGATCAGCATTGCTGCGGTGAA 
TACGTTCCCGGGCCTTGTACACACCGCCCGTCACGTCACGAAAGTCGGTAACACCCGAAGCCGGTGGCCC 
AACCCCTTGTGGGAGGGAGCTGTCGAAGGTGGGACTGGCGATTG 
 
> Contig - A1A3_1492-27  
GTTGGGCCACCGGCTTCAGGTGTTACCGACTTTCGTGACGTGACGGGCGGTGTGTACAAGGCCCGGGAAC 
GTATTCACCGCAGCAATGCTGATCTGCGATTACTAGCAACTCCGACTTCATGGGGTCGAGTTGCAGACCC 
CAATCCGAACTGAGACCGGCTTTTTGAGATTCGCTCCGCCTCGCGGCATCGCAGCTCATTGTACCGGCCA 
TTGTAGCACGTGTGCAGCCCAAGACATAAGGGGCATGATGACTTGACGTCGTCCCCACCTTCCTCCGAGT 
TGACCCCGGCAGTCTCCTGTGAGTCCCCATCACCCCGAAGGGCATGCTGGCAACACAGAACAAGGGTTGC 
GCTCGTTGCGGGACTTAACCCAACATCTCACGACACGAGCTGACGACAGCCATGCACCACCTGTATACCG 
ACCACAAGGGGGGCACCATCTCTGATGCTTTCCGGTATATGTCAAGCCTTGGTAAGGTTCTTCGCGTTGC 
GTCGAATTAAGCCACATGCTCCGCTGCTTGTGCGGGCCCCCGTCAATTCCTTTGAGTTTTAGCCTTGCGG 
CCGTACTCCCCAGGCGGGGAACTTAATGCGTTAGCTGCGGCACCGACGACGTGGAATGTCGCCAACACCT 
AGTTCCCAACGTTTACGGCGTGGACTACCAGGGTATCTAATCCTGTTCGCTCCCCACGCTTTCGCTCCTC 
AGCGTCAGTAATGGCCCAGAGATCCGCCTTCGCCACCGGTGTTCCTCCTGATATCTGCGCATTTCACCGC 
TACACCAGGAATTCCGATCTCCCCTACCACACTCTAGCTAGCCCGTATCGAATGCAGACCCGGGGTTAAG 
CCCCGGGCTTTCACATCCGACGTGACAAGCCGCCTACGAGCTCTTTACGCCCAATAATTCCGGACAACGC 
TTGCGCCCTACGTATTACCGCGGCTGCTGGCACGTAGTTAGCCGGCGCTTCTTCTGCAGGTACCGTCACT 
TTCGCTTCTTCCCTGCTGAAAGAGGTTTACAACCCGAAGGCCGTCATCCCTCACGCGGCGTCGCTGCATC 
AGGCTTTCGCCCATTGTGCAATATTCCCCACTGCTGCCTCCCGTAGGAGTCTGGGCCGTGTCTCAGTCCC 
AGTGTGGCCGGTCGCCCTCTCAGGCCGGCTACCCGTCGTCGCCTTGGTAGGCCATTACCCCACCAACAAG 
CTGATAGGCCGCGGGCTCATCCTTCACCGCCGGAGCTTTTAACCCCGTCCCATGCAGGACAGAGTGTTAT 
CCGGTATTAGACCCCGTTTCCAGGGCTTGTCCCAGAGTGAAGGGCAGATTGCCCACGTGTTACTCACCCG 
TTCGCCACTAATCCACCCCGAAAGGATTCAT 
55 
 
 
 
> Contig - PAB_518-800  
AGATTGAACGCTGGCGGCAGGCCTAACACATGCAAGTCGAGCGGATGAAGGGAGCTTGCTCCTGGATTCA 
GCGGCGGACGGGTGAGTAATGCCTAGGAATCTGCCTGGTAGTGGGGGATAACGTCCGGAAACGGGCGCTA 
ATACCGCATACGTCCTGAGGGAGAAAGTGGGGGATCTTCGGACCTCACGCTATCAGATGAGCCTAGGTCG 
GATTAGCTAGTTGGTGGGGTAAAGGCCTACCAAGGCGACGATCCGTAACTGGTCTGAGAGGATGATCAGT 
CACACTGGAACTGAGACACGGTCCAGACTCCTACGGGAGGCAGCAGTGGGGAATATTGGACAATGGGCGA 
AAGCCTGATCCAGCCATGCCGCGTGTGTGAAGAAGGTCTTCGGATTGTAAAGCACTTTAAGTTGGGAGGA 
AGGGCAGTAAGTTAATACCTTGCTGTTTTGACGTTACCAACAGAATAAGCACCGGCTAACTTCGTGCCAG 
CAGCCGCGGTAATACGAAGGGTGCAAGCGTTAATCGGAATTACTGGGCGTAAAGCGCGCGTAGGTGGTTC 
AGCAAGTTGGATGTGAAATCCCCGGGCTCAACCTGGGAACTGCATCCAAAACTACTGAGCTAGAGTACGG 
TAGAGGGTGGTGGAATTTCCTGTGTAGCGGTGAAATGCGTAGATATAGGAAGGAACACCAGTGGCGAAGG 
CGACCACCTGGACTGATACTGACACTGAGGTGCGAAAGCGTGGGGAGCAAACAGGATTAGATACCCTGGT 
AGTCCACGCCGTAAACGATGTCGACTAGCCGTTGGGATCCTTGAGATCTTAGTGGCGCAGCTAACGCGAT 
AAGTCGACCGCCTGGGGAGTACGGCCGCAAGGTTAAAACTCAAATGAATTGACGGGGGCCCGCACAAGCG 
GTGGAGCATGTGGTTTAATTCGAAGCAACGCGAAGAACCTTACCTGGCCTTGACATGCTGAGAACTTTCC 
AGAGATGGATTGGTGCCTTCGGGAACTCAGACACAGGTGCTGCATGGCTGTCGTCAGCTCGTGTCGTGAG 
ATGTTGGGTTAAGTCCCGTAACGAGCGCAACCCTTGTCCTTAGTTACCAGCACCTCGGGTGGGCACTCTA 
AGGAGACTGCCGGTGACAAACCGGAGGAAGGTGGGGATGACGTCAAGTCATCATGGCCCTTACGGCCAGG 
GCTACACACGTGCTACAATGGTCGGTACAAAGGGTTGCCAAGCCGCGAGGTGGAGCTAATCCCATAAAAC 
CGATCGTAGTCCGGATCGCAGTCTGCAACTCGACTGCGTGAAGTCGGAATCGCTAGTAATCGTGAATCAG 
AATGTCACGGTGAATACGTTCCCGGGCCTTGTACACACCGCCCGTCACACCATGGGGAGTGGGTTGCTCC 
AGAAGTAGCTAGTCTAACCGCAAGGGGGACGGTTACCACGGAGTGATCATGATGGGTG 
> Contig - PAB_1492-27  
GACTTGCTACTTCTGGAGCAACCCACTCCCATGGTGTGACGGGCGGTGTGTACAAGGCCCGGGAACGTAT 
TCACCGTGACATTCTGATTCACGATTACTAGCGATTCCGACTTCACGCAGTCGAGTTGCAGACTGCGATC 
CGGACTACGATCGGTTTTATGGGATTAGCTCCACCTCGCGGCTTGGCAACCCTTTGTACCGACCATTGTA 
GCACGTGTGTAGCCCTGGCCGTAAGGGCCATGATGACTTGACGTCATCCCCACCTTCCTCCGGTTTGTCA 
CCGGCAGTCTCCTTAGAGTGCCCACCCGAGGTGCTGGTAACTAAGGACAAGGGTTGCGCTCGTTACGGGA 
CTTAACCCAACATCTCACGACACGAGCTGACGACAGCCATGCAGCACCTGTGTCTGAGTTCCCGAAGGCA 
CCAATCCATCTCTGGAAAGTTCTCAGCATGTCAAGGCCAGGTAAGGTTCTTCGCGTTGCTTCGAATTAAA 
CCACATGCTCCACCGCTTGTGCGGGCCCCCGTCAATTCATTTGAGTTTTAACCTTGCGGCCGTACTCCCC 
AGGCGGTCGACTTATCGCGTTAGCTGCGCCACTAAGATCTCAAGGATCCCAACGGCTAGTCGACATCGTT 
TACGGCGTGGACTACCAGGGTATCTAATCCTGTTTGCTCCCCACGCTTTCGCACCTCAGTGTCAGTATCA 
GTCCAGGTGGTCGCCTTCGCCACTGGTGTTCCTTCCTATATCTACGCATTTCACCGCTACACAGGAAATT 
CCACCACCCTCTACCGTACTCTAGCTCAGTAGTTTTGGATGCAGTTCCCAGGTTGAGCCCGGGGATTTCA 
CATCCAACTTGCTGAACCACCTACGCGCGCTTTACGCCCAGTAATTCCGATTAACGCTTGCACCCTTCGT 
ATTACCGCGGCTGCTGGCACGAAGTTAGCCGGTGCTTATTCTGTTGGTAACGTCAAAACAGCAAGGTATT 
AACTTACTGCCCTTCCTCCCAACTTAAAGTGCTTTACAATCCGAAGACCTTCTTCACACACGCGGCATGG 
CTGGATCAGGCTTTCGCCCATTGTCCAATATTCCCCACTGCTGCCTCCCGTAGGAGTCTGGACCGTGTCT 
CAGTTCCAGTGTGACTGATCATCCTCTCAGACCAGTTACGGATCGTCGCCTTGGTAGGCCTTTACCCCAC 
CAACTAGCTAATCCGACCTAGGCTCATCTGATAGCGTGAGGTCCGAAGATCCCCCACTTTCTCCCTCAGG 
ACGTATGCGGTATTAGCGCCCGTTTCCGGACGTTATCCCCCACTACCAGGCAGATTCCTAGGCATTACTC 
ACCCGTCCGCCGCTGAATCCAGGAGCAAGCTCCCT 
 
56 
 
 
 
> Contig - PM58B_518-800  
AGGACGAACGCTGGCGGCGTGCTTAACACATGCAAGTCGAACGATGAAGCCTTTCGGGGTGGATTAGTGG 
CGAACGGGTGAGTAACACGTGGGCAATCTGCCCTTCACTCTGGGACAAGCCCTGGAAACGGGGTCTAATA 
CCGGATAACACTCTGTCCTGCATGGGACGGGGTTAAAAGCTCCGGCGGTGAAGGATGAGCCCGCGGCCTA 
TCAGCTTGTTGGTGGGGTAATGGCCTACCAAGGCGACGACGGGTAGCCGGCCTGAGAGGGCGACCGGCCA 
CACTGGGACTGAGACACGGCCCAGACTCCTACGGGAGGCAGCAGTGGGGAATATTGCACAATGGGCGAAA 
GCCTGATGCAGCGACGCCGCGTGAGGGATGACGGCCTTCGGGTTGTAAACCTCTTTCAGCAGGGAAGAAG 
CGAAAGTGACGGTACCTGCAGAAGAAGCGCCGGCTAACTACGTGCCAGCAGCCGCGGTAATACGTAGGGC 
GCAAGCGTTGTCCGGAATTATTGGGCGTAAAGAGCTCGTAGGCGGCTTGTCACGTCGGATGTGAAAGCCC 
GGGGCTTAACCCCGGGTCTGCATTCGATACGGGCTAGCTAGAGTGTGGTAGGGGAGATCGGAATTCCTGG 
TGTAGCGGTGAAATGCGCAGATATCAGGAGGAACACCGGTGGCGAAGGCGGATCTCTGGGCCATTACTGA 
CGCTGAGGAGCGAAAGCGTGGGGAGCGAACAGGATTAGATACCCTGGTAGTCCACGCCGTAAACGTTGGG 
AACTAGGTGTTGGCGACATTCCACGTCGTCGGTGCCGCAGCTAACGCATTAAGTTCCCCGCCTGGGGAGT 
ACGGCCGCAAGGCTAAAACTCAAAGGAATTGACGGGGGCCCGCACAAGCAGCGGAGCATGTGGCTTAATT 
CGACGCAACGCGAAGAACCTTACCAAGGCTTGACATATACCGGAAAGCATCAGAGATGGTGCCCCCCTTG 
TGGTCGGTATACAGGTGGTGCATGGCTGTCGTCAGCTCGTGTCGTGAGATGTTGGGTTAAGTCCCGCAAC 
GAGCGCAACCCTTGTTCTGTGTTGCCAGCATGCCCTTCGGGGTGATGGGGACTCACAGGAGACTGCCGGG 
GTCAACTCGGAGGAAGGTGGGGACGACGTCAAGTCATCATGCCCCTTATGTCTTGGGCTGCACACGTGCT 
ACAATGGCCGGTACAATGAGCTGCGATGCCGCGAGGCGGAGCGAATCTCAAAAAGCCGGTCTCAGTTCGG 
ATTGGGGTCTGCAACTCGACCCCATGAAGTCGGAGTTGCTAGTAATCGCAGATCAGCATTGCTGCGGTGA 
ATACGTTCCCGGGCCTTGTACACACCGCCCGTCACGTCACGAAAGTCGGTAACACCCGAAGCCGGTGGCC 
CAACCCCTTGTGGGAGGGAGCTGTCGAAGGTGGGACTGGCGA 
 
> Contig - PM58B_1492-27  
CGACTTTCGTGACGTGACGGGCGGTGTGTACAAGGCCCGGGAACGTATTCACCGCAGCAATGCTGATCTG 
CGATTACTAGCAACTCCGACTTCATGGGGTCGAGTTGCAGACCCCAATCCGAACTGAGACCGGCTTTTTG 
AGATTCGCTCCGCCTCGCGGCATCGCAGCTCATTGTACCGGCCATTGTAGCACGTGTGCAGCCCAAGACA 
TAAGGGGCATGATGACTTGACGTCGTCCCCCACCTTCCTCCGAGTTGACCCCGGCAGTCTCCTGTGAGTC 
CCCATCACCCCGAAGGGCATGCTGGCAACACAGAACAAGGGTTGCGCTCGTTGCGGGACTTAACCCAACA 
TCTCACGACACGAGCTGACGACAGCCATGCACCACCTGTATACCGACCACAAGGGGGGCACCATCTCTGA 
TGCTTTCCGGTATATGTCAAGCCTTGGTAAGGTTCTTCGCGTTGCGTCGAATTAAGCCACATGCTCCGCT 
GCTTGTGCGGGCCCCCGTCAATTCCTTTGAGTTTTAGCCTTGCGGCCGTACTCCCCAGGCGGGGAACTTA 
ATGCGTTAGCTGCGGCACCGACGACGTGGAATGTCGCCAACACCTAGTTCCCAACGTTTACGGCGTGGAC 
TACCAGGGTATCTAATCCTGTTCGCTCCCCACGCTTTCGCTCCTCAGCGTCAGTAATGGCCCAGAGATCC 
GCCTTCGCCACCGGTGTTCCTCCTGATATCTGCGCATTTCACCGCTACACCAGGAATTCCGATCTCCCCT 
ACCACACTCTAGCTAGCCCGTATCGAATGCAGACCCGGGGTTAAGCCCCGGGCTTTCACATCCGACGTGA 
CAAGCCGCCTACGAGCTCTTTACGCCCAATAATTCCGGACAACGCTTGCGCCCTACGTATTACCGCGGCT 
GCTGGCACGTAGTTAGCCGGCGCTTCTTCTGCAGGTACCGTCACTTTCGCTTCTTCCCTGCTGAAAGAGG 
TTTACAACCCCGAAGGCCGTCATCCCTCACGCGGGCGTCGCTGCATCAGGGCTTTCGCCCATTGTGCAAT 
ATTCCCCACTGCTGCCTCCCGTAGGAGTCTGGGCCGTGTCTCAGTCCCAGTGTGGCCGGTCGCCCTCTCA 
GGCCGGCTACCCGTCGTCGCCTTGGTAGGCCATTACCCCACCAACAAGCTGATAGGCCGCGGGCTCATCC 
TTCACCGCCGGAGCTTTTAACCCCGTCCCATGCAGGACAGAGTGTTATCCGGTATTAGACCCCGTTTCCA 
GGGCTTGTCCCAGAGTGAAGGGCAGATTGCCCACGTGTTACTCACCCGTTCGCCACTAATCCACCCCGAA 
AGGATTCATCGTC 
 
57 
 
 
 
> Contig - RA003_518-800  
AGGACGAACGCTGGCGGCGTGCCTAATACATGCAAGTCGAGCGAACAGAAGGGAGCTTGCTCCCGGATGT 
TAGCGGCGGACGGGTGAGTAACACGTGGGTAACCTGCCTGTAAGACTGGGATAACTCCGGGAAACCGGAG 
CTAATACCGGATAGTTCCTTGAACCGCATGGTTCAAGGATGAAAGACGGTTTCGGCTGTCACTTACAGAT 
GGACCCGCGGCGCATTAGCTAGTTGGTGGGGTAATGGCTCACCAAGGCGACGATGCGTAGCCGACCTGAG 
AGGGTGATCGGCCACACTGGGACTGAGACACGGCCCAGACTCCTACGGGAGGCAGCAGTAGGGAATCTTC 
CGCAATGGACGAAAGTCTGACGGAGCAACGCCGCGTGAGTGATGAAGGTTTTCGGATCGTAAAGCTCTGT 
TGTTAGGGAAGAACAAGTGCGAGAGTAACTGCTCGCACCTTGACGGTACCTAACCAGAAAGCCACGGCTA 
ACTACGTGCCAGCAGCCGCGGTAATACGTAGGTGGCAAGCGTTGTCCGGAATTATTGGGCGTAAAGGGCT 
CGCAGGCGGTTTCTTAAGTCTGATGTGAAAGCCCCCGGCTCAACCGGGGAGGGTCATTGGAAACTGGGAA 
ACTTGAGTGCAGAAGAGGAGAGTGGAATTCCACGTGTAGCGGTGAAATGCGTAGAGATGTGGAGGAACAC 
CAGTGGCGAAGGCGACTCTCTGGTCTGTAACTGACGCTGAGGAGCGAAAGCGTGGGGAGCGAACAGGATT 
AGATACCCTGGTAGTCCACGCCGTAAACGATGAGTGCTAAGTGTTAGGGGGTTTCCGCCCCTTAGTGCTG 
CAGCTAACGCATTAAGCACTCCGCCTGGGGAGTACGGTCGCAAGACTGAAACTCAAAGGAATTGACGGGG 
GCCCGCACAAGCGGTGGAGCATGTGGTTTAATTCGAAGCAACGCGAAGAACCTTACCAGGTCTTGACATC 
CTCTGACAACCCTAGAGATAGGGCTTTCCCTTCGGGGACAGAGTGACAGGTGGTGCATGGTTGTCGTCAG 
CTCGTGTCGTGAGATGTTGGGTTAAGTCCCGCAACGAGCGCAACCCTTGATCTTAGTTGCCAGCATTTAG 
TTGGGCACTCTAAGGTGACTGCCGGTGACAAACCGGAGGAAGGTGGGGATGACGTCAAATCATCATGCCC 
CTTATGACCTGGGCTACACACGTGCTACAATGGACAGAACAAAGGGCTGCGAGACCGCAAGGTTTAGCCA 
ATCCCATAAATCTGTTCTCAGTTCGGATCGCAGTCTGCAACTCGACTGCGTGAAGCTGGAATCGCTAGTA 
ATCGCGGATCAGCATGCCCGGGGGAATACGTTTCCCGGGCCTTGTACACACCGCCCGTCACACCACGAGA 
GTTTGTAACACCCGAAGTCGGTGAGGTAACCTTTATGGAGCCAGCCGCCGAAGGTGGGACAGATGATTGG 
GGTGAATCTAAGGGG 
 
> Contig - RA003_1492-27  
ACTCTCGTGGTGTGACGGGCGGTGTGTACAAGGCCCGGGAACGTATTCACCGCGGCATGCTGATCCGCGA 
TTACTAGCGATTCCAGCTTCACGCAGTCGAGTTGCAGACTGCGATCCGAACTGAGAACAGATTTATGGGA 
TTGGCTAAACCTTGCGGTCTCGCAGCCCTTTGTTCTGTCCATTGTAGCACGTGTGTAGCCCAGGTCATAA 
GGGGCATGATGATTTGACGTCATCCCCACCTTCCTCCGGTTTGTCACCGGCAGTCACCTTTAGAGTGCCC 
AACTAAATGCTGGCAACTAAGATCAAGGGTTGCGCTCGTTGCGGGACTTAACCCCAACATCTCACGACAC 
GAGCTGACGACAACCATGCACCACCTGTCACTCTGTCCCCGAAGGGAAAGCCCTATCTCTAGGGTTGTCA 
GAGGATGTCAAGACCTGGTAAGGTTCTTCGCGTTGCTTCGAATTAAACCACATGCTCCACCGCTTGTGCG 
GGCCCCCGTCAATTCCTTTGAGTTTCAGTCTTGCGACCGTACTCCCCAGGCGGAGTGCTTAATGCGTTAG 
CTGCAGCACTAAGGGGCGGAAACCCCCTAACACTTAGCACTCATCGTTTACGGCGTGGACTACCAGGGTA 
TCTAATCCTGTTCGCTCCCCACGCTTTCGCTCCTCAGCGTCAGTTACAGACCAGAGAGTCGCCTTCGCCA 
CTGGTGTTCCTCCACATCTCTACGCATTTCACCGCTACACGTGGAATTCCACTCTCCTCTTCTGCACTCA 
AGTTTCCCAGTTTCCAATGACCCTCCCCGGTTGAGCCGGGGGCTTTCACATCAGACTTAAGAAACCGCCT 
GCGAGCCCTTTACGCCCAATAATTCCGGACAACGCTTGCCACCTACGTATTACCGCGGCTGCTGGCACGT 
AGTTAGCCGTGGCTTTCTGGTTAGGTACCGTCAAGGTGCGAGCAGTTACTCTCGCACTTGTTCTTCCCTA 
ACAACAGAGCTTTACGATCCGAAAACCTTCATCACTCACGCGGCGTTGCTCCGTCAGACTTTCGTCCATT 
GCGGAAGATTCCCTACTGCTGCCTCCCGTAGGAGTCTGGGCCGTGTCTCAGTCCCAGTGTGGCCGATCAC 
CCTCTCAGGTCGGCTACGCATCGTCGCCTTGGTGAGCCATTACCCCACCAACTAGCTAATGCGCCGCGGG 
TCCATCTGTAAGTGACAGCCGAAACCGTCTTTCATCCTTGAACCATGCGGTTCAAGGAACTATCCGGTAT 
TAGCTCCGGTTTCCCGGAGTTATCCCAGTCTTACAGGCAGGTTACCCACGTGTTACTCACCCGTCCGCCG 
CTAACATCCGGGAGC 
